Program
HSK44459
A development code. Also written as “HSK44459 Cream”, “HSK44459 dose 1” and “HSK44459 dose 2”.
Its studies are mostly in Psoriasis · Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis · Dermatitis, Atopic, led by Haisco Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 108 open or running | phase 3since Mar 25, 2026 | Aug 15, 2024 | Mar 2027phase 2 · NCT07623486 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2024First study: phase 1 study in HealthyFirst studyNCT06858657 · 82 enrolled · China
- Jan 6, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT06764862 · 186 enrolled · China
- Mar 17, 2025Phase 2 study in Behcet's DiseaseNCT06902428 · 120 planned
- May 21, 2025Phase 2 study in Dermatitis, AtopicNCT06996912 · 150 enrolled · China
- Jun 5, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT07019090 · 120 planned
- Jul 9, 2025Phase 2 study in Bechet's DiseaseNCT07070739 · 120 planned
- Aug 27, 2025Phase 2 study in PsoriasisNCT07150988 · 150 planned · China
- Mar 25, 20262 phase 3 studiesPhase 3 reachedNCT07503587, NCT07519070
- May 29, 2026Phase 2 study in PsoriasisNCT07623486 · 180 enrolled · China
Ahead
- Nov 6, 2026Primary completion: phase 2 study in PsoriasisNCT07150988
- Mar 2027Primary completion: phase 2 study in PsoriasisNCT07623486
- Jul 2027Primary completion: phase 2 study in Bechet's DiseaseNCT07070739
- Apr 5, 2028Primary completion: phase 3 study in IPFNCT07519070
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623486Psoriasis · China | 2 | Active, not recruiting | Mar 2027 | 180 |
| NCT07519070IPF | 3 | Not yet recruiting | Apr 5, 2028 | 420 |
| NCT07503587Progressive Pulmonary Fibrosis | 3 | Not yet recruiting | Dec 30, 2028 | 378 |
| NCT07150988Psoriasis · China | 2 | Not yet recruiting | Nov 6, 2026 | 150 |
| NCT07070739Bechet's Disease | 2 | Not yet recruiting | Jul 2027 | 120 |
| NCT07019090Idiopathic Pulmonary Fibrosis | 2 | Not yet recruiting | Oct 31, 2026 | 120 |
| NCT06996912Dermatitis, Atopic · China | 2 | Active, not recruiting | Jan 20, 2026 | 150 |
| NCT06902428Behcet's Disease | 2 | Not yet recruiting | Jun 5, 2026 | 120 |
| NCT06764862Idiopathic Pulmonary Fibrosis · China | 2 | Completed | Feb 12, 2026 | 186 |
| NCT06858657Healthy · China | 1 | Completed | Nov 18, 2024 | 82 |
How it is read
Names in the registry
- “HSK44459”, 8 entries
- “HSK44459 Cream”, 1 entry
- “HSK44459 dose 1”, 1 entry
- “HSK44459 dose 2”, 1 entry
- “HSK44459 dose 3”, 1 entry
Codes read as this program: HSK44459.
Conditions, from the studies’ own filings
- Psoriasis, 2 studies
- Idiopathic Pulmonary Fibrosis, 2 studies
- Pulmonary Fibrosis, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.